A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven movement of the legs and upper extremities. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
Financial Summary
| Share Statistics | ONWRY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $195.4 | $416.1 | 27% |
|
| Shares Out (Mil) | 57.2 | 41.6 | 51% |
|
| Institutional Ownership | 46.9% | 83.1% | 20% |
|
| Float (Mil) | 54.7 | 35.6 | 49% |
|
| Beta | 0.85 | 0.88 | 51% |
|
| Avg Daily Volume (000s) | 9 | 333 | 17% |
|
| Price Change (52-week) |
na | 65.0% | na |
|
| Growth | ONWRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 45.0% | 11.8% | 95% |
|
| Net Income (5yr) | (14.9%) | (5.9%) | 25% |
|
| EPS (5yr) | 31.1% | 10.2% | 82 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.7% | (15.6%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ONWRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $119 | 7% |
|
| Net Income (TTM) (Mil) | ($49) | ($9) | 16% |
|
| EPS (TTM) | ($1.051) | ($0.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($46) | ($3) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $10 | $1 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $15 | $22 | 31% |
|
| Enterprise Value (Q1) (Mil) | $162 | $371 | 24% |
|
| Valuation | ONWRY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.00 | na |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.6 | na |
|
| Ratios | ONWRY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 80.8% | 58.5% | 89% |
|
| Net Margin | (771.8%) | (6.9%) | 1% |
|
| ROA | (55.1%) | (13.4%) | 11% |
|
| ROE | (85.6%) | (13.6%) | 10% |
|
| Liabilities to Assets | 34.6% | 46.1% | 26% |
|
| F-Score | na | 4 | na |
|
Onward Medical N.V. did not pass any screens on 9/2/2026.
